Rhenman & Partners Asset Management Ab Xencor Inc Transaction History

Rhenman & Partners Asset Management Ab

$840 Million
Q1 2025

A detailed history of Rhenman & Partners Asset Management Ab transactions in Xencor Inc stock. As of the latest transaction made, Rhenman & Partners Asset Management Ab holds 195,750 shares of XNCR stock, worth $1.77 Million. This represents 0.25% of its overall portfolio holdings.

Number of Shares

195,750

Previous 195,750 -0.0%

Holding current value

$1.77 Million

Previous $4.5 Million 53.71%

% of portfolio

0.25%

Previous 0.47%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	SELL	$19.43 - $26.84 $155,440 - $214,720	-8,000 Reduced 3.93%	195,750 $4.5 Million
Q3 2024 Nov 13, 2024	SELL	$15.7 - $21.65 $235,500 - $324,750	-15,000 Reduced 6.86%	203,750 $4.1 Million
Q1 2024 May 14, 2024	SELL	$18.65 - $26.52 $116,562 - $165,750	-6,250 Reduced 2.78%	218,750 $4.84 Million
Q3 2023 Nov 13, 2023	BUY	$20.08 - $25.39 $4.34 Million - $5.48 Million	216,000 Added 2400.0%	225,000 $4.53 Million
Q3 2023 Nov 09, 2023	SELL	$20.08 - $25.39 $4.34 Million - $5.48 Million	-216,000 Reduced 96.0%	9,000 $181,000
Q2 2023 Aug 11, 2023	SELL	$24.77 - $29.9 $619,250 - $747,500	-25,000 Reduced 10.0%	225,000 $5.62 Million
Q1 2023 May 11, 2023	SELL	$25.95 - $36.95 $1.14 Million - $1.63 Million	-44,076 Reduced 14.99%	250,000 $6.97 Million
Q3 2022 Nov 14, 2022	SELL	$24.62 - $32.44 $145,848 - $192,174	-5,924 Reduced 1.97%	294,076 $8.23 Million
Q2 2022 Aug 12, 2022	SELL	$19.74 - $29.01 $861,374 - $1.27 Million	-43,636 Reduced 12.7%	300,000 $8.21 Million
Q1 2022 May 13, 2022	SELL	$26.68 - $41.63 $2.84 Million - $4.43 Million	-106,364 Reduced 23.64%	343,636 $9.17 Million
Q4 2021 Feb 11, 2022	SELL	$33.67 - $43.44 $1.92 Million - $2.48 Million	-57,002 Reduced 11.24%	450,000 $18.3 Million
Q3 2021 Nov 12, 2021	BUY	$30.65 - $35.68 $5.12 Million - $5.96 Million	167,002 Added 49.12%	507,002 $16.6 Million
Q2 2021 Aug 13, 2021	BUY	$34.33 - $44.68 $3.6 Million - $4.69 Million	105,000 Added 44.68%	340,000 $11.7 Million
Q1 2021 May 14, 2021	SELL	$40.81 - $53.88 $993,356 - $1.31 Million	-24,341 Reduced 9.39%	235,000 $10.1 Million
Q4 2020 Jan 19, 2021	SELL	$36.63 - $47.63 $24,139 - $31,388	-659 Reduced 0.25%	259,341 $11.3 Million
Q2 2020 Jul 16, 2020	SELL	$27.76 - $33.42 $1.12 Million - $1.35 Million	-40,325 Reduced 13.43%	260,000 $8.42 Million
Q1 2020 Apr 16, 2020	SELL	$20.69 - $37.79 $200,175 - $365,618	-9,675 Reduced 3.12%	300,325 $8.97 Million
Q4 2019 Jan 17, 2020	BUY	$32.75 - $41.43 $244,871 - $309,772	7,477 Added 2.47%	310,000 $10.7 Million
Q3 2019 Oct 16, 2019	SELL	$33.73 - $46.27 $582,483 - $799,036	-17,269 Reduced 5.4%	302,523 $10.2 Million
Q2 2019 Jul 22, 2019	SELL	$29.6 - $40.93 $182,720 - $252,660	-6,173 Reduced 1.89%	319,792 $13.1 Million
Q1 2019 Apr 11, 2019	BUY	$27.85 - $38.09 $2.99 Million - $4.09 Million	107,428 Added 49.16%	325,965 $10.1 Million
Q4 2018 Feb 05, 2019	BUY	$32.39 - $42.05 $281,242 - $365,120	8,683 Added 4.14%	218,537 $7.9 Million
Q3 2018 Oct 03, 2018	SELL	$35.69 - $47.65 $235,161 - $313,965	-6,589 Reduced 3.04%	209,854 $8.18 Million
Q2 2018 Jul 20, 2018	SELL	$28.41 - $42.41 $2.37 Million - $3.54 Million	-83,557 Reduced 27.85%	216,443 $8.01 Million
Q1 2018 Apr 11, 2018	SELL	$21.18 - $33.78 $370,650 - $591,150	-17,500 Reduced 5.51%	300,000 $8.99 Million
Q4 2017 Jan 19, 2018	BUY	$19.29 - $24.83 $1.3 Million - $1.68 Million	67,500 Added 27.0%	317,500 $6.96 Million
Q3 2017 Oct 13, 2017	BUY	$19.61 - $23.35 $4.9 Million - $5.84 Million	250,000	250,000 $5.73 Million

Others Institutions Holding XNCR

# of Institutions

210

Shares Held

78.4M

Call Options Held

3.4K

Put Options Held

1.9K

View Full List

About Xencor Inc

Ticker XNCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,698,100
Market Cap $540M
Description
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...

More about XNCR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhenman & Partners Asset Management Ab, based on Form 13F filings with the SEC.

News

Stay updated on Rhenman & Partners Asset Management Ab with notifications on news.

Account

Rhenman & Partners Asset Management Ab Xencor Inc Transaction History